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Background: Human obesity is due to a complex interaction among environmental, behavioral, developmental
and genetic factors, including the interaction of leptin (LEP) and leptin receptor (LEPR). Several LEPR mutations and
polymorphisms have been described in patients with early onset severe obesity and hyperphagic eating behavior;
however, some contradictory findings have also been reported. In the present study we explored the association of
six LEPR gene polymorphisms in patients with morbid obesity.
Findings: Twenty eight patients with morbid obesity and 56 non-obese Mexican Mestizo individuals were included.
Typing of rs1137100, rs1137101, rs1805134, Ser492Thr, rs1805094 and rs1805096 LEPR polymorphisms was
performed by PCR and allele specific hybridization. The LEPR Ser492Thr polymorphism was monomorphic with the
presence of only the Ser492Thr-G allele. Allele C and genotype T/C for rs1805134 polymorphism were associated
with susceptibility to morbid obesity (p = 0.02 and p = 0.03, respectively). No association was observed with any
haplotype. Linkage disequilibrium (LD) showed that five polymorphisms (rs1137100, rs1137101, rs1805134, rs1805094
and rs1805096) were in absolute (D’ = 1) but none in perfect (r2 = 1) LD.
Conclusions: Our results suggest that rs1805134 polymorphism could be involved in the development of morbid
obesity, whilst none of the alleles of the LEPR gene, rs1137100, rs1137101, rs1805094 and rs1805096 were associated as
risk factors. However, more studies are necessary to confirm or reject this hypothesis.
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Human obesity is due to a complex interaction among en-
vironmental, behavioral, developmental and genetic fac-
tors, the latter contributing to 40–70 % of the obese
phenotype [1–3]. Leptin (LEP) is a hormone specifically
produced by adipocytes, and its serum concentration is
proportional to body fat mass which, in turn, has its
amount regulated by the hypothalamic effects of LEP.
Intravenous administration of LEP reduces appetite; while
its deficiency increases food intake [4]. Its action occurs
through the leptin receptor (LEPR), which is encoded by
the LEPR gene. LEPR is a single-transmembrane-domain* Correspondence: aolivod@yahoo.com
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tissue distribution and several alternatively spliced iso-
forms [5].
Several LEPR mutations have been described in pa-
tients with early-onset of severe obesity and hyperphagic
eating behavior [6, 7]. In contrast, a protective influence
of two polymorphisms (rs1137100 and rs1137101) to
higher blood pressure levels in men has been identified,
increasing the protection when the carriers have the ar-
ginine allele in the two single nucleotide polymorphisms
(SNPs) [8]. Thereby, several SNPs have been studied,
and their replication in detail across different popula-
tions, for their potential association with obesity and its
complication, has been stated. However, some contra-
dictory findings have also been reported, adding the fact
that there are scarce studies in non-Caucasian popula-
tions; therefore, the lack of data on this subject empha-
sizes the need for studies among and across different
ethnic groups [9, 10]. In this work we explored theThis article is distributed under the terms of the Creative Commons Attribution
ons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Alleles, genotypes and haplotypes frequencies of LEPR SNPs in a Co-dominant model
Patients (n = 28) Controls (n = 56) p valuea OR (95 % CI)b
Alleles
rs1137100-C (Lys109Arg) 0.45 0.43 0.99 1.08 (0.51–2.30)
rs1137100-T 0.55 0.57 0.99 0.92 (0.43–1.96)
rs1137101-G (Gln223Arg) 0.43 0.39 0.79 1.18 (0.58–2.39)
rs1137101-A 0.57 0.61 0.79 0.85 (0.41–1.72)
rs1805134-C (Ser343Ser)c 0.17 0.06 0.02 3.41 (1.11–10.49)
rs1805134-T 0.83 0.94 0.02 0.29 (0.09–0.90)
Ser492Thr-G 1 1 – –
Ser492Thr-C 0 0 – –
rs1805094-G (Lys656Asn) 0.22 0.12 0.13 2.02 (0.89–4.59)
rs1805094-C 0.78 0.88 0.13 0.49 (0.22–1.13)
rs1805096-G (Pro1019Pro) 0.40 0.40 0.93 0.97 (0.48–1.95)
rs1805096-A 0.60 0.60 0.93 1.03 (0.51–2.07)
Genotypes
rs1137100 C/C 0.05 0.10 0.87 0.66 (0.07–6.01)
rs1137100 C/T 0.79 0.65 0.42 1.85 (0.19–0.59)
rs1137100 T/T 0.16 0.25 0.65 0.64 (0.16–2.57)
rs1137101 A/A 0.32 0.30 0.88 1.09 (0.38–3.16)
rs1137101 A/G 0.50 0.61 0.54 0.65 (0.24–1.76)
rs1137101 G/G 0.18 0.09 0.45 2.28 (0.55–9.43)
rs1805134 T/Td 0.65 0.89 0.03 0.24 (0.07–0.83)
rs1805134 T/Cd 0.35 0.11 0.03 4.01 (1.20–13.41)
Ser492Thr G/G 1.00 1.00 – –
rs1805094 C/C 0.59 0.77 0.13 0.43 (0.17–1.13)
rs1805094 C/G 0.38 0.22 0.17 2.19 (0.83–5.77)
rs1805094 G/G 0.03 0.01 0.82 2.09 (0.13–34.61)
rs1805096 A/A 0.33 0.33 0.84 1.05 (0.37–2.92)
rs1805096 A/G 0.54 0.54 0.82 1.01 (0.38–2.66)
rs1805096 G/G 0.13 0.13 0.80 0.99 (0.23–4.20)
Haplotypese
CGTGCA 0.266 0.271 0.94 0.97 (0.47–2.01)
TATGCG 0.173 0.223 0.47 0.74 (0.32–1.69)
TATGCA 0.108 0.106 0.98 1.01 (0.36–2.88)
CATGCG 0.078 0.117 0.44 0.64 (0.20–2.00)
TATGGA 0.084 0.088 0.92 0.94 (0.30–3.01)
TGCGCA 0.073 0.058 0.70 1.28 (0.36–4.62)
CATGCA 0.037 0.041 0.91 0.91 (0.17–4.92)
TGTGCG 0.037 0.029 0.79 1.27 (0.22–7.53)
TATGGG 0.047 0.024 0.39 2.12 (0.37–12.03)
TACGGG 0.032 0.005 0.13 7.97 (0.34–185.4)
TGTGCA 0.005 0.016 0.56 0.34 (0.01–15.99)
*p value with Yates correction; bOdds ratio (95 % confidence interval); cStatistical power = 0.632; dStatistical power = 0.679; eLEPR haplotypes: rs1137100-rs1137101-
rs1805134-Ser492Thr-rs1805094-rs1805096. Characters in bold and italics indicate statistically significant values
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morbid obesity compared with non-obese Mexican Mes-
tizo adults.
Blood samples were obtained from 28 patients with
morbid obesity (mean age 39.6 ± 6.6 years, mean body
mass index [BMI] 42.7 ± 6.5 Kg/m2) and 56 non-fat
(mean age 32.7 ± 14.4, mean BMI 21.5 ± 1.5 Kg/m2)
healthy unrelated volunteers. The sex of patients and
controls was 89.7 and 93.3 % females, respectively. All
participants were unrelated, with no consanguinity at all,
and none couple was included. In addition to obesity,
two patients presented hypothyroidism, one patient pre-
sented type 2 diabetes mellitus and arterial hypertension
and one patient presented fat liver. This work complies
with the current health laws of Mexico, and was
approved by the Ethics and Research Committees of the
Hospital General “Dr. Manuel Gea Gonzalez” with the
reference number 04-92-2009. All participants were
informed about the objectives of the study and were
included only after providing written informed consent.
DNA was obtained from 10 ml of EDTA-peripheral blood
using proteinase K and phenol/chloroform extraction [11].
The LEPR polymorphisms rs1137100 (Lys109Arg),
rs1137101 (Gln223Arg), rs1805134 (Ser343Ser), Ser492Thr
and rs1805096 (Pro1019Pro) were detected by PCR-
restriction fragment length polymorphism (RFLP) technique,
using primers described by Gotoda et al. [12] and Matsuoka
et al. [13]. For allele determination of rs8179183 (Lys656Asn)
SNP, a dot–blot format and the chemiluminescence method
was used, employing the specific probes Lys656Asn-G: 5′-Fig. 1 Linkage disequilibrium (LD) in LEPR polymorphisms between obese
4.2. Within each diamond the pairwise standardized coefficient of LD (D’) o
color coding was used for the Haploview LD plots with the confidence bo
the logarithm of the odds are in color: white = strong evidence of recombi
r2 LD plots white (r2 = 0), shades of grey (0 < r2 < 1), black (r2 = 1). A marker p
0.5, and strong LD if |D’| is 0.5 or above (i.e. at least half the maximum valuCTATGAAAAAGGAGAAAAATG-3' and Lys656Asn-C: 5'-
CTATGAAAAACGAGAAAAATG-3′ ddUTP-Digoxigenin
labelled [14, 15].
Allele frequencies (AF) and genotype frequencies (GF)
were calculated by direct counting and were compared
between patients and controls of each group. Chi-square
analysis with Yate’s correction, considering p ≤ 0.05 as
the minimum level of significance, was performed; exact
Fisher test was used when appropriate. Relative risk was
calculated as an odds ratio (OR). Ninety-five percent
confidence intervals (95 % CI) were obtained by using
Cornfield’s approximation. Haplotypes and linkage dis-
equilibrium (LD) blocks were determined by confidence
interval method using Haploview 4.2 software [16].
Table 1 summarizes the significant associations
found between alleles, genotypes and haplotypes ob-
served in patients with morbid obesity and in con-
trols. Polymorphism Ser492Thr was monomorphic
with the only presence of Ser492Thr-G allele. Allele
C and genotype T/C for rs1805134 SNP were associ-
ated with susceptibility to morbid obesity (p = 0.02
and p = 0.03, respectively). Regarding the haplotype
frequency, no association was observed; however,
when shorter combinations were analyzed, haplotype
rs1137101G-rs1805134C becomes associated with sus-
ceptibility (p = 0.036; OR [95 % CI] 3.4 [1.02–11.14]).
Finally, according to LD plots generated in Haploview
4.2 (Fig. 1), the LEPR gene showed that five SNPs
(rs1137100, rs1137101, rs1805134, rs1805094 and
rs1805096) were in absolute but none in perfect LD.and control groups. The pairwise LD plot was created by Haploview
r the correlation coefficient (r2) is presented in percentage. Standard
unds color scheme, for the D’ plot, numbers are representative LD and
nation; light grey = uninformative; dark grey = strong evidence of LD; for
air is said to show moderate or usable LD if |D’| is between 0.33 and
e)
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population exhibits predisposition towards obesity ([17,
18], http://www.who.int/topics/obesity/en/). Therefore, it
is important to study the genetic mechanisms that pre-
dispose individuals to this pathology. In the present
study, of the six SNPs analyzed, only allele C and geno-
type T/C for rs1805134 (Ser343Ser) SNP was associated
with morbid obesity. Interestingly, this polymorphism
has been scanty studied in obesity; when association be-
tween serum lipids and LEP/LEPR gene polymorphisms
in obese Japanese children was studied, the rs1805134
SNPs showed a significant relationship with serum lipid
profile, since lower triglyceride levels were obtained in
rs1805134 C/C homozygotes [19]. In another study per-
formed in Spanish adults with obesity, no significant
case–control differences were found in allele/genotype
frequencies for rs1137100, rs1137101, rs1805134 and
rs8179183 SNPs [20]. Since rs1805134 SNP addresses a
synonymous amino acid change and, according to our
results, it was in absolute LD with both flanking SNPs
(rs1137100 and rs1805096) in the LEPR gene, it suggests
that SNPs have not been affected by recombination
events, which is in concordance with the literature. The
present observations allow us to speculate about the
presence of others polymorphisms, probably located in
introns, close to rs1805134 SNP in absolute and perfect
LD, which might regulate the expression of exon 9 of
LEPR gene, as it has been described for other Eukaryotes
genes [21].
Regarding rs1137100, rs1137101 and rs8179183 SNPs,
our data are similar with those reported in others Mexican
populations; Guizar-Mendoza et al. [22] assessed rs1137101
and rs1805096 LEPR polymorphisms in Mexican adoles-
cents from Guanajuato state, finding no differences in the
genotype frequencies of these SNPs between obese and
non-obese participants. Furthermore, another study in
Mexican children and adolescents from Colima state, ana-
lyzed rs1137100, rs1137101 and rs8179183 SNPs, and no
statistically significant association with obesity was found in
any of the alleles [18].
The main limitation of the present study was the small
sample size; nevertheless we were able to demonstrate
statistically significant differences with an adequate
power between case and control groups. Rosmond [10]
has made harsh criticisms on the association with risk
factors of case–control genetic studies, highlighting that
the current literature linking central obesity to genetic
variants has many reports of associations that either can-
not be reproduced or corroborated. The present study,
as opposed to Rosmond’s criticism, does replicate the
findings reported by other researchers in the same eth-
nic group, supporting the consistency of allele and geno-
type frequency for some LEPR polymorphisms in a
specific group of participants; therefore, we propose thatthe rs1805134 SNP is interesting and might be involved
in morbid obesity; however, more studies are necessary
to confirm or reject this hypothesis.
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